QRxPharma Announces MOXDUO® License With Aspen
QRxPharma Announces MOXDUO® License With Aspen
Filed under: drug abuse treatment outcome study
QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. The Company's product portfolio includes both late and early stage …
Read more on Sacramento Bee
Amgen, Inc. (AMGN): Amgen's CEO Presents at Morgan Stanley Healthcare …
Filed under: drug abuse treatment outcome study
And we've made other acquisitions as well, Micromet which brings to us a very attractive platform for treating oncology for reaching oncology targets, the most advanced of those programs as one for leukemia, Acute Lymphoblastic Leukemia, the data there …
Read more on Seeking Alpha
Strong Acquisition Target Poised To Challenge In Fat Loss And Skin Care Markets
Filed under: drug abuse treatment outcome study
Orexigen Therapeutics (NASDAQ: OREX) is also developing its weight loss product Contrave, which has completed Phase III clinical trials and is currently being studied in a cardiovascular outcomes trial. … can be approved, you must conduct a …
Read more on Trefis